Submitted by Anonymous (not verified) on 29 October 2025 - 14:35
Human medicines European public assessment report (EPAR): Rybrevant, amivantamab, Date of authorisation: 09/12/2021, Revision: 10, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Rybrevant, amivantamab, Date of authorisation: 09/12/2021, Revision: 10, Status: Authorised